C4 Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

C4 Therapeutics 의 총 주주 지분은 $242.7M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $376.1M 및 $133.4M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$255.64m
주식	US$242.66m
총 부채	US$133.40m
총 자산	US$376.06m

최근 재무 상태 업데이트

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Oct 02

Recent updates

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

Nov 15

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Nov 06

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Oct 02

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

Aug 09

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Aug 03

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

재무 상태 분석

단기부채: CCCC 의 단기 자산 ( $273.2M )이 단기 부채( $43.3M ).

장기 부채: CCCC 의 단기 자산( $273.2M )이 장기 부채( $90.1M ).

부채 대 자본 내역 및 분석

부채 수준: CCCC 부채가 없습니다.

부채 감소: CCCC 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: CCCC 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: CCCC 23.5 1.8 23.5 % 매년.

C4 Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Recent updates

C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

Consensus revenue estimates increase by 24%, EPS downgraded

C4 Therapeutics, Inc. Announces First Patient Dosed in CFT8919 Clinical Trial

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics, Inc. Announces Executive Changes

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

C4 Therapeutics, Inc. Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept from Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at European Society for Medical Oncology Congress 2024

C4 Therapeutics, Inc. Announces Board Changes

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

New minor risk - Profitability

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics, Inc. Announces Board and Committee Changes

Consensus EPS estimates upgraded to US$1.59 loss, revenue downgraded

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

Price target decreased by 30% to US$11.88

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

C4 Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Consensus revenue estimates increase by 12%

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Price target increased by 8.0% to US$16.00

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 13% to US$15.50

C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.

C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

New major risk - Share price stability

C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors

Price target decreased by 13% to US$16.20

Price target decreased by 12% to US$16.40

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Price target decreased by 31% to US$13.11

C4 Therapeutics, Inc. Announces Upcoming Data Presentations for CFT8634 and CFT7455

Price target increased by 7.4% to US$20.40

Consensus revenue estimates decrease by 27%, EPS upgraded

Price target decreased by 9.3% to US$17.23

C4 Therapeutics, Inc. Appoints Mary Christian as Senior Vice President, Regulatory

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

C4 Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for CFT8919

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell Small Cap Comp Value Index

C4 Therapeutics, Inc. Appoints Leonard (Len) Reyno as Chief Medical Officer, Effective July 10, 2023

C4 Therapeutics, Inc. announced that it expects to receive $25 million in funding from Betta Pharmaceuticals Co., Ltd.

Price target decreased by 8.1% to US$19.23

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

Consensus revenue estimates decrease by 16%, EPS upgraded

Price target decreased by 30% to US$14.83

Price target increased by 10% to US$23.73

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

C4 Therapeutics, Inc. Announces Executive Changes

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC(Tm) Degrader, in BRAF V600 Mutant Solid Tumors

Price target decreased to US$23.46

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

C4 Therapeutics, Inc. Appoints Laura Bessen and Donna Grogan to its Board of Directors

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 2000 Growth Index

C4 Therapeutics, Inc. Announces Alain J. Cohen Withdrawal as a Director Nominee for Re-Election At the 2022 Annual Meeting

C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-Null Tumors